Results: 4

1.
Figure 1

Figure 1. From: Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.

Flow chart of patient selection from the Cancer and Leukemia Group B (CALGB) trial 89803 for inclusion in the study cohort. Q1 = Questionnaire 1, Q2 = Questionnaire 2.

Kimmie Ng, et al. J Natl Cancer Inst. 2011 October 19;103(20):1540-1551.
2.
Figure 2

Figure 2. From: Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.

Survival outcomes of statin users and nonusers from the Cancer and Leukemia Group B (CALGB) trial 89803. Kaplan–Meier curves of A) disease-free survival and B) overall survival of patients (n = 842) after a median follow-up of 6.5 years. Error bars represent 95% confidence intervals. Statistical significance was measured by the log-rank test. All P values were two-sided.

Kimmie Ng, et al. J Natl Cancer Inst. 2011 October 19;103(20):1540-1551.
3.
Figure 3

Figure 3. From: Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.

Survival outcomes of statin users and nonusers from the Cancer and Leukemia Group B (CALGB) trial 89803 stratified by KRAS mutation status. Kaplan–Meier curves of A) disease-free survival in KRAS wild-type patients, B) disease-free survival in KRAS mutant patients, C) overall survival in KRAS wild-type patients, and D) overall survival in KRAS mutant patients in those with tissue available for KRAS mutation testing (n = 394) after a median follow-up of 6.5 years. Error bars represent 95% confidence intervals. Statistical significance was measured by the log-rank test. All P values were two-sided.

Kimmie Ng, et al. J Natl Cancer Inst. 2011 October 19;103(20):1540-1551.
4.
Figure 4

Figure 4. From: Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.

Risk of cancer recurrence and death among statin users and nonusers across strata of predictors of cancer outcome. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer recurrence and death (disease-free survival) were calculated by Cox proportional hazards regression models. Wald test of cross-product terms was used to calculate Pinteraction and was two-sided. ASA = aspirin; BMI = body mass index; ECOG = Eastern Cooperative Oncology Group; IFL = irinotecan, bolus 5-FU, LV; MET = metabolic equivalent task; PS = performance status; T = depth of invasion through bowel wall; 5-FU/LV = bolus 5-fluorouracil/leucovorin; .

Kimmie Ng, et al. J Natl Cancer Inst. 2011 October 19;103(20):1540-1551.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk